{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:40:51Z","timestamp":1791308451488,"version":"4.3.1"},"reference-count":98,"publisher":"Consilium Medicum","issue":"5","license":[{"start":{"date-parts":[[2019,5,15]],"date-time":"2019-05-15T00:00:00Z","timestamp":1557878400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Terapevticheskii arkhiv"],"abstract":"<jats:p>Nowadays, there is increased interest in the connection of gout and asymptomatic hyperuricemia with comorbid conditions such as diabetes mellitus, cardiovascular diseases, hypertension, chronic kidney disease and other. Studies conducted over the past few decades suggest that not only gout, but also asymptomatic hyperuricemia can significantly worsen the prognosis in patients with cardiovascular diseases, as the deposition of urate crystals can be both an immediate cause and a factor in the progression of renal failure. In that way, the timely appointment of urate - lowering therapy and achieving the target serum uric acid level can not only affect joint damage, but also can significantly slow the progression of life - threatening comorbid conditions.<\/jats:p>","DOI":"10.26442\/00403660.2019.05.000232","type":"journal-article","created":{"date-parts":[[2019,6,26]],"date-time":"2019-06-26T11:37:45Z","timestamp":1561549065000},"page":"120-128","source":"Crossref","is-referenced-by-count":16,"title":["Comorbidity in gout and hyperuricemia: prevalence, causes, prospects of urate lowering therapy"],"prefix":"10.26442","volume":"91","author":[{"given":"M S","family":"Eliseev","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A M","family":"Novikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"18344","published-online":{"date-parts":[[2019,5,15]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2017"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Culleton B.F, Larson M.G, Kannel W.B, Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med. 1999;131(1):7-13. PMID: 10391820","DOI":"10.7326\/0003-4819-131-1-199907060-00003"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1136\/annrh"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/art.22466"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-29955-w"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-2107"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205827"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/srep25766"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00555.2014"},{"key":"ref10","unstructured":"\u0415\u043b\u0438\u0441\u0435\u0435\u0432 \u041c.\u0421., \u0411\u0430\u0440\u0441\u043a\u043e\u0432\u0430 \u0412.\u0413. \u041d\u0430\u0440\u0443\u0448\u0435\u043d\u0438\u044f \u0443\u0433\u043b\u0435\u0432\u043e\u0434\u043d\u043e\u0433\u043e \u043e\u0431\u043c\u0435\u043d\u0430 \u043f\u0440\u0438 \u043f\u043e\u0434\u0430\u0433\u0440\u0435: \u0447\u0430\u0441\u0442\u043e\u0442\u0430 \u0432\u044b\u044f\u0432\u043b\u0435\u043d\u0438\u044f \u0438 \u043a\u043b\u0438\u043d\u0438\u0447\u0435\u0441\u043a\u0438\u0435 \u043e\u0441\u043e\u0431\u0435\u043d\u043d\u043e\u0441\u0442\u0438. \u0422\u0435\u0440\u0430\u043f\u0435\u0432\u0442\u0438\u0447\u0435\u0441\u043a\u0438\u0439 \u0430\u0440\u0445\u0438\u0432. 2010;82(5):50-4."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.4239\/wjd.v5.i5.697"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/s12950-016-0142-3"},{"key":"ref13","unstructured":"\u0411\u0430\u0440\u0441\u043a\u043e\u0432\u0430 \u0412.\u0413., \u0415\u043b\u0438\u0441\u0435\u0435\u0432 \u041c.\u0421., \u041a\u0443\u0434\u0430\u0435\u0432\u0430 \u0424.\u041c. \u0438 \u0434\u0440. \u0412\u043b\u0438\u044f\u043d\u0438\u0435 \u043c\u0435\u0442\u0444\u043e\u0440\u043c\u0438\u043d\u0430 \u043d\u0430 \u0442\u0435\u0447\u0435\u043d\u0438\u0435 \u043f\u043e\u0434\u0430\u0433\u0440\u044b \u0438 \u0438\u043d\u0441\u0443\u043b\u0438\u043d\u043e\u0440\u0435\u0437\u0438\u0441\u0442\u0435\u043d\u0442\u043d\u043e\u0441\u0442\u044c. \u041a\u043b\u0438\u043d\u0438\u0447\u0435\u0441\u043a\u0430\u044f \u043c\u0435\u0434\u0438\u0446\u0438\u043d\u0430. 2009;87(7):41-6."},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Matsuura F, Yamashita S, Nakamura T, et al. Effects of visceral fat accumulation on uric acid metabolism in male obese subjects: visceral fat obesity is linked more closely to overproduction of uric acid than subcutaneous fat obesity. Metabolism. 1998;47:929-33. doi: 10.1016\/ S0026-0495(98)90346-8","DOI":"10.1016\/S0026-0495(98)90346-8"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Rasheed H, Hughes K, Flynn T.J, Merriman T.R. Mendelian randomization provides no evidence for a causal role of serum urate in increasing serum triglyceride levels. Circ Cardiovasc Genet. 2014;7(6):830-7. doi: 10.1161\/ CIRCGENETICS.114.000556","DOI":"10.1161\/CIRCGENETICS.114.000556"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.2337\/db12-1814"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M112.399899"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1096\/fj.13-243634"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.5603\/CJ.2018.0116"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-015-0610-9"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1186\/ar3806"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.2174\/1874303X01609010012"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Kang D.H, Chen W. Uric acid and chronic kidney disease: new understanding of an old problem. Semin Nephol. 2011;31:447-552.","DOI":"10.1016\/j.semnephrol.2011.08.009"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Mazzali M, Hughes J, Kim Y.G, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal - independent mechanism. Hypertension. 2001;38:1101-6.","DOI":"10.1161\/hy1101.092839"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Kang D.H, Nakagawa T, Feng L, et al. A role for uric acid in the progression of renal disease. J Am Soc Nephrol. 2002;13:2888-97.","DOI":"10.1097\/01.ASN.0000034910.58454.FD"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2369-15-122"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfu352"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205252"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1177\/2047487313514895"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Choi H.K, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation. 2007;116(8):894-900. doi: 10.1161\/ CIRCULATIONAHA.107.703389","DOI":"10.1161\/CIRCULATIONAHA.107.703389"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202421"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.17116\/terarkh201789510-19"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-017-0890-9"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jare.2017.04.008"},{"key":"ref35","unstructured":"Perez-Ruiz F, et al. Failure to Reach Serum Urate Target Is Associated with Elevated Mortality in Gout. Arthritis Rheum. ABSTRACT SUPPLEMENT. 2018;70(S9):954-5."},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1002\/art.22014"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.122770"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2011-000282"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-7133.2011.00262.x"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev418"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2016"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Nakagawa T, Mazzali M, Kang D-H, et al. Hyperuricemia causes glomerular hypertrophy in the rat. Am J Nephrol. 2003;23:2-7. doi: 10.115 9\/000066303","DOI":"10.1159\/000066303"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00454.2007"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms5642"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1093\/ajh\/hpy157"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1093\/ajh\/hpy143"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1038\/hr.2012.135"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2015.07.059"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.5551\/jat.33951"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-005308"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000000701"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2013.08.023"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1097\/MCA.0000000000000084"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"Kim S.Y, Guevara J.P, Kim K.M, Choi H.K, Heitjan D.F, Albert D.A. Hyperuricemia and risk of stroke: a systematic review and meta - analysis. Arthritis Rheum. 2009;61(7):885-92.","DOI":"10.1002\/art.24612"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1002\/art.39581"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20344"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.115.06852"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2016.07.026"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2015.11.003"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"Kleber M.E, Delgado G, Grammer T.B, Silbernagel G, Huang J, Kramer B.K, Ritz E, Marz W. Uric acid and cardiovascular events: a Mendelian randomization study. J Am Soc Nephrol. 2015;26(11):2831-8.","DOI":"10.1681\/ASN.2014070660"},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"Yan D, Wang J, Jiang F, Zhang R, Wang T, Wang S, Peng D, He Z, Chen H, Bao Y, et al. A causal relationship between uric acid and diabetic macrovascular disease in Chinese type 2 diabetes patients: a Mendelian randomization analysis. Int J Cardiol. 2016;214:194-9.","DOI":"10.1016\/j.ijcard.2016.03.206"},{"key":"ref64","doi-asserted-by":"crossref","unstructured":"Stack A.G, Hanley A, Casserly L.F, Cronin C.J, Abdalla A.A, Kiernan T.J, Murthy B.V, Hegarty A, Hannigan A, Nguyen H.T. Independent and conjoint associations of gout and hyperuricaemia with total and cardiovascular mortality. QJM. 2013;106(7):647-58.","DOI":"10.1093\/qjmed\/hct083"},{"key":"ref65","doi-asserted-by":"crossref","unstructured":"Yang Q, Kottgen A, Dehghan A, Smith A.V, Glazer N.L, Chen M.H, Chasman D.I, Aspelund T, Eiriksdottir G, Harris T.B, et al. Multiple genetic loci influence serum urate levels and their relationship with gout and cardiovascular disease risk factors. Circ Cardiovasc Genet. 2010;3(6):523-30.","DOI":"10.1161\/CIRCGENETICS.109.934455"},{"key":"ref66","doi-asserted-by":"crossref","unstructured":"Pfister R, Barnes D, Luben R, Forouhi N.G, Bochud M, Khaw K.T, Wareham N.J, Langenberg C. No evidence for a causal link between uric acid and type 2 diabetes: a Mendelian randomization approach. Diabetologia. 2011;54(10):2561-9.","DOI":"10.1007\/s00125-011-2235-0"},{"key":"ref67","doi-asserted-by":"crossref","unstructured":"Hughes K, Flynn T, de Zoysa J, Dalbeth N, Merriman T.R. Mendelian randomization analysis associates increased serum urate, due to genetic variation in uric acid transporters, with improved renal function. Kidney Int. 2014;85(2):344-51.","DOI":"10.1038\/ki.2013.353"},{"key":"ref68","doi-asserted-by":"crossref","unstructured":"Sedaghat S, Pazoki R, Uitterlinden A.G, Hofman A, Stricker B.H, Ikram M.A, Franco O.H, Dehghan A. Association of uric acid genetic risk score with blood pressure: the Rotterdam study. Hypertension. 2014;64(5):1061-6.","DOI":"10.1161\/HYPERTENSIONAHA.114.03757"},{"key":"ref69","doi-asserted-by":"crossref","unstructured":"Sluijs I, Holmes M.V, van der Schouw Y.T, Beulens J.W, Asselbergs F.W, Huerta J.M, Palmer T.M, Arriola L, Balkau B, Barricarte A, et al. A Mendelian randomization study of circulating uric acid and type 2 diabetes. Diabetes. 2015;64(8):3028-36.","DOI":"10.2337\/db14-0742"},{"key":"ref70","doi-asserted-by":"crossref","unstructured":"Keenan T, Zhao W, Rasheed A, Ho W.K, Malik R, Felix J.F, Young R, Shah N, Samuel M, Sheikh N, et al. Causal assessment of serum urate levels in cardiometabolic diseases through a Mendelian randomization study. J Am Coll Cardiol. 2016;67(4):407-16.","DOI":"10.1016\/j.jacc.2015.10.086"},{"key":"ref71","doi-asserted-by":"crossref","unstructured":"White J, Sofat R, Hemani G, Shah T, Engmann J, Dale C, Shah S, Kruger F.A, Giambartolomei C, Swerdlow D.I, et al. Plasma urate concentration and risk of coronary heart disease: a Mendelian randomisation analysis. Lancet Diabetes Endocrinol. 2016;4(4):327-36.","DOI":"10.1016\/S2213-8587(15)00386-1"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-5922.2011.00277.x"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60391-1"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000001077"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000001270"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1038\/srep04554"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1016\/j.phar"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/8603164"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.09.066"},{"key":"ref80","unstructured":"De Abajo F.J, Gil M.J, Rodriguez A, et al. Allopurinol use and risk of non - fatal acute myocardial infarction. Heart. 2015;101:67985. doi: 10.1136\/ heartjnl-2014-306670"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2015.11.003"},{"key":"ref82","doi-asserted-by":"crossref","unstructured":"Thanassoulis G, Brophy J.M, Richard H, Pilote L. Gout, allopurinol use, and heart failure outcomes. Arch Intern Med. 2010;170:1358-64. doi: 10.11 36\/bmjopen-2011-000282","DOI":"10.1001\/archinternmed.2010.198"},{"key":"ref83","doi-asserted-by":"crossref","unstructured":"Zhang J, Dierckx R, Mohee K, Clark A.L, Cleland J.G. Xanthine oxidase inhibition for the treatment of cardiovascular disease: an updated systematic review and meta - analysis. ESC Heart Fail. 2017 Feb;4(1):40-5.","DOI":"10.1002\/ehf2.12112"},{"key":"ref84","doi-asserted-by":"crossref","unstructured":"Givertz M.M, Anstrom K.J, Redfield M.M, et al. Effects of xanthine oxidase inhibition in hyperuricemic heart failure patients: the EXACT-HF study. Circulation. 2015;131:1763-71.","DOI":"10.1161\/CIRCULATIONAHA.114.014536"},{"key":"ref85","doi-asserted-by":"crossref","unstructured":"Agarwal V, Hans N, Messerli F.H. Effect of allopurinol on blood pressure: a systematic review and meta - analysis. J Clin Hypertens. 2013;15:435-42.","DOI":"10.1111\/j.1751-7176.2012.00701.x"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2016.1243803"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1001\/jama.300.8.924"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.1161\/HYPER"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.10771016"},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-015-0047-z"},{"key":"ref91","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gft378"},{"key":"ref92","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2014.11.016"},{"key":"ref93","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0187550"},{"key":"ref94","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-015-1095-1"},{"key":"ref95","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2015.05.017"},{"key":"ref96","doi-asserted-by":"publisher","DOI":"10.6002\/ect.2016.0367"},{"key":"ref97","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfx313"},{"key":"ref98","doi-asserted-by":"crossref","unstructured":"Juge P.A, Truchetet M.E, Pillebout E, et al. Efficacy and safety of febuxostat in 73 gouty patients with stage 4\/5 chronic kidney disease: A retrospective study of 10 centers. Joint Bone Spine. 2017;84(5):595-8. doi: 10.1016\/ j.jbspin.2016.09.020","DOI":"10.1016\/j.jbspin.2016.09.020"}],"container-title":["Terapevticheskii arkhiv"],"original-title":[],"link":[{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/viewFile\/33655\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/viewFile\/33655\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T21:57:58Z","timestamp":1634162278000},"score":1,"resource":{"primary":{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/view\/33655"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,15]]},"references-count":98,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2019,5,15]]}},"URL":"https:\/\/doi.org\/10.26442\/00403660.2019.05.000232","relation":{},"ISSN":["2309-5342","0040-3660"],"issn-type":[{"value":"2309-5342","type":"electronic"},{"value":"0040-3660","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5,15]]}}}